SARS-CoV-2 Inactivated Vaccine (Vero cells) developed by Beijing Sinovac Biotech Co., Ltd was approved for marketing with conditions.

In order to promote the improvement of the technology and ensure the quality of medical laboratory testing, Shanghai Clinical Laboratory Center invited 10 hospitals to participate in the multi institute performance evaluation and validation seminar.

Sansure Biotech enters the pet market, pet medical is expected to become the company's new growth pole.

Two recent papers in The Lancet and Science have brought herd immunity back into The picture: a Brazilian city that was once thought to be herd immunity is once again experiencing a peak.

On January 30, 2021, Amoy Diagnostics and AstraZeneca signed a strategic cooperation on HRD testing and companion diagnosis for ovarian cancer.

The Hurun Research Institute released the 2020 Hurun Global 500 recently, a list of the 500 most valuable non-state-controlled companies in the world.

Do I need to be vaccinated against COVID-19?

Due to January 18, a number of companies in the biomedical sector have issued performance forecasts.

Recently,Thermo Fisher Scientific announced that it plans to acquire Mesa Biotech,INC with USD 450 million in cash and a milestone payment of USD 100 million.

HOB Biotech Group (HOB) and Shanghai Liferiver Biotech Co., Ltd. were successfully listed on Shanghai Stock Exchange in January 2021.

January 18, 2021, Pfizer China and Cepheid China formally signed a strategic cooperation agreement in Shanghai.

Sansure Biotech released an announcement of performance increase on January 18, and it is expected that the net profit attributable to the owners of the parent company will be realized from 2.556 billion yuan to 2.8626 billion yuan in 2020.

In January 2021, Beijing Targeting One Biotechnology Co., Ltd. (hereinafter referred to as " Targeting One") announced the completion of 150 million round B financing.

There is a vaccine race, but not between countries. It is a race between humans to develop vaccines and novel coronavirus.

Recently, Shanghai Runda Medical Technology Co., Ltd. disclosed to the public that the company will acquire part of the shares of two IVD companies in Anhui and Shanghai at a price of 328 million.